TOKYO (Reuters) - Japan's health ministry has approved dexamethasone, a cheap and widely used steroid, as a second treatment of COVID-19 after a trial in Britain showed the drug reduced death rates in hospitalised patients.
The ministry included dexamethasone as an option for treatment along with antiviral drug remdesivir in a recent revision to its handbook. The revision was widely reported by Japanese media on Wednesday.
Already a subscriber? Log in
Get 20% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
